PrometDobitKGVKUVEBITDividendaAkcijeKapitalizacija tržištaDugovanjeObavezeKapital društvaAAQSzaposleniROEROAROCE
Vir Biotechnology Akcija

Vir Biotechnology Dugovanje 2025

Vir Biotechnology Dugovanje

-222,95 USD

Тикер

VIR

ISIN

US92764N1028

WKN

A2PS0P

U godini 2025 dug kompanije Vir Biotechnology iznosio je -222,95 USD, što je promena od -7,71% u poređenju sa ukupnim dugom od -241,58 USD u prethodnoj godini.

Vir Biotechnology Aktienanalyse

Šta radi Vir Biotechnology?

Vir Biotechnology Inc. is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. The translation is: Vir Biotechnology Inc. is a biopharmaceutical company that focuses on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. Vir Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Dugovanje у детаљу

Razumevanje strukture zaduženosti kompanije Vir Biotechnology

Ukupna zaduženost kompanije Vir Biotechnology odnosi se na akumulirane finansijske obaveze koje preduzeće duguje spoljnim stranama. To može uključivati kratkoročne i dugoročne kredite, obveznice, pozajmice i druge finansijske instrumente. Procena zaduženosti preduzeća je ključna za ocenu njegovog finansijskog zdravlja, profila rizika i sposobnosti finansiranja operacija i ekspanzije.

Godišnji poređenje

Analiza strukture zaduženosti kompanije Vir Biotechnology tokom godina pruža uvide u finansijsku strategiju i stabilnost preduzeća. Smanjenje zaduženosti može ukazivati na finansijsku snagu i operativnu efikasnost, dok povećanje može ukazivati na investicije u rast ili potencijalne finansijske izazove.

Uticaj na investicije

Investitori pažljivo prate zaduženost kompanije Vir Biotechnology, jer ona može uticati na profil rizika i prinosa preduzeća. Prekomerna zaduženost može dovesti do finansijskih teškoća, dok umerena i dobro upravljana zaduženost može biti katalizator za rast i ekspanziju. To je čini ključnim aspektom u evaluacijama investicija.

Interpretacija fluktuacija zaduženosti

Promene u nivou zaduženosti kompanije Vir Biotechnology mogu biti rezultat različitih operativnih i strateških faktora. Povećanje zaduženosti može biti usmereno na finansiranje projekata ekspanzije ili povećanje operativne kapacitete, dok smanjenje može ukazivati na realizaciju profita ili pristup minimiziranju finansijskog rizika i leveragea.

Često postavljana pitanja o Vir Biotechnology akciji

Kolike su dugovi kompanije Vir Biotechnology ove godine?

Vir Biotechnology ima ove godine dug od -222,95 USD.

Koliko su iznosili dugovi kompanije Vir Biotechnology u poređenju sa prethodnom godinom?

Dug Vir Biotechnology je u poređenju sa prošlom godinom povećan za -7,71% pao.

Koje posledice visoki dugovi imaju za investitore od Vir Biotechnology?

Visok dug može predstavljati rizik za investitore Vir Biotechnology jer može dovesti kompaniju u slabiju finansijsku poziciju i uticati na njenu sposobnost da ispunjava svoje obaveze.

Koje posledice niske zaduženosti imaju za investitore Vir Biotechnology?

Niske dugove znači da Vir Biotechnology ima snažnu finansijsku poziciju i sposoban je da ispuni svoje obaveze bez prekomernog opterećenja svojih finansija.

Kako povećanje dugova od Vir Biotechnology utiče na kompaniju?

Povećanje duga od Vir Biotechnology može uticati na finansijsku situaciju kompanije i dovesti do većeg opterećenja za njene finansije.

Kako smanjenje dugova od Vir Biotechnology utiče na preduzeće?

Smanjenje duga od Vir Biotechnology može ojačati finansijsku situaciju kompanije i poboljšati njenu sposobnost da ispuni svoje finansijske obaveze.

Koji su neki faktori koji utiču na dugove Vir Biotechnology?

Neki od faktora koji mogu uticati na dugove Vir Biotechnology uključuju, između ostalog, investicije, akvizicije, operativne troškove i razvoj prihoda.

Zašto su dugovi Vir Biotechnology tako važni za investitore?

Dugovanja kompanije Vir Biotechnology su važna za investitore, jer su indikator finansijske stabilnosti preduzeća i pružaju informacije o tome kako kompanija ispunjava svoje finansijske obaveze.

Koje strateške mere Vir Biotechnology može preduzeti kako bi promenio dugove?

Da bi promenila svoje dugove, Vir Biotechnology može preduzeti različite mere poput smanjenja troškova, povećanja prihoda, prodaje imovine, privlačenja investicija ili sklapanja partnerstava. Važno je da kompanija temeljno preispita svoju finansijsku situaciju kako bi odredila najbolje strateške mere za restrukturiranje svojih dugova.

Kolika je dividenda koju isplaćuje Vir Biotechnology?

U poslednjih 12 meseci, Vir Biotechnology je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Vir Biotechnology će verovatno isplatiti dividendu od 0 USD.

Kolika je dividendna prinosa za Vir Biotechnology?

Dividendski prinos od Vir Biotechnology trenutno iznosi .

Kada Vir Biotechnology isplaćuje dividendu?

Vir Biotechnology isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Vir Biotechnology?

Vir Biotechnology je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Vir Biotechnology?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Vir Biotechnology?

Vir Biotechnology se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Vir Biotechnology kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Vir Biotechnology od 24. 7. 2025. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 24. 7. 2025..

Kada je Vir Biotechnology poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 24. 7. 2025..

Kolika je bila dividenda od Vir Biotechnology u godini 2024?

U godini 2024 kompanija Vir Biotechnology je isplatila 0 USD kao dividende.

U kojoj valuti Vir Biotechnology isplaćuje dividendu?

Dividende od Vir Biotechnology se isplaćuju u USD.

Plansovi za štednju u akcijama nude atraktivnu mogućnost za investitore da dugoročno izgrade bogatstvo. Jedna od glavnih prednosti je takozvani efekat prosečne cene: investiranjem redovnog fiksnog iznosa u akcije ili fondove akcija, automatski se kupuju više deonica kada su cene niske i manje kada su visoke. To može dovesti do povoljnijeg prosečnog cena po deonici tokom vremena. Pored toga, plansovi za štednju u akcijama omogućuju čak i malim ulagačima pristup skupim akcijama, pošto je moguće učestvovati već sa malim iznosima. Redovno investiranje takođe podstiče disciplinovanu strategiju ulaganja i pomaže da se izbegnu emocionalne odluke, kao što su impulsivno kupovanje ili prodaja. Osim toga, investitori profitiraju od potencijalnog povećanja vrednosti akcija kao i od isplata dividendi, koje se mogu reinvestirati, što pojačava efekat kamate na kamatu i time rast investiranog kapitala.

Andere Kennzahlen von Vir Biotechnology

Naša analiza akcija za akciju Vir Biotechnology Promet uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Vir Biotechnology Promet. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: